Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.04
DGX's Cash to Debt is ranked lower than
57% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. DGX: 0.04 )
DGX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.04

Equity to Asset 0.43
DGX's Equity to Asset is ranked higher than
60% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. DGX: 0.43 )
DGX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.62
Current: 0.43

0.3
0.62
Interest Coverage 9.10
DGX's Interest Coverage is ranked higher than
54% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. DGX: 9.10 )
DGX' s 10-Year Interest Coverage Range
Min: 1.82   Max: 16.85
Current: 9.1

1.82
16.85
F-Score: 6
Z-Score: 2.93
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.63
DGX's Operating margin (%) is ranked higher than
92% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. DGX: 13.63 )
DGX' s 10-Year Operating margin (%) Range
Min: -37.2   Max: 20.64
Current: 13.63

-37.2
20.64
Net-margin (%) 6.96
DGX's Net-margin (%) is ranked higher than
86% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. DGX: 6.96 )
DGX' s 10-Year Net-margin (%) Range
Min: -38.73   Max: 11.88
Current: 6.96

-38.73
11.88
ROE (%) 12.68
DGX's ROE (%) is ranked higher than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. DGX: 12.68 )
DGX' s 10-Year ROE (%) Range
Min: -4.13   Max: 21.63
Current: 12.68

-4.13
21.63
ROA (%) 5.41
DGX's ROA (%) is ranked higher than
84% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. DGX: 5.41 )
DGX' s 10-Year ROA (%) Range
Min: -1.6   Max: 11.74
Current: 5.41

-1.6
11.74
ROC (Joel Greenblatt) (%) 86.45
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DGX: 86.45 )
DGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 24.96   Max: 142.92
Current: 86.45

24.96
142.92
Revenue Growth (%) 4.00
DGX's Revenue Growth (%) is ranked higher than
73% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. DGX: 4.00 )
DGX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 15.4
Current: 4

0
15.4
EBITDA Growth (%) 9.40
DGX's EBITDA Growth (%) is ranked higher than
81% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. DGX: 9.40 )
DGX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 44.5
Current: 9.4

0
44.5
EPS Growth (%) 9.40
DGX's EPS Growth (%) is ranked higher than
81% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. DGX: 9.40 )
DGX' s 10-Year EPS Growth (%) Range
Min: 0   Max: 62.3
Current: 9.4

0
62.3
» DGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DGX Guru Trades in Q4 2013

Steven Cohen 63,695 sh (+1380.59%)
Paul Tudor Jones 26,689 sh (+641.36%)
Joel Greenblatt 279,188 sh (+533.63%)
John Rogers 268,053 sh (+447.73%)
Richard Pzena 1,215,050 sh (+81.17%)
Jeff Auxier 80,350 sh (+31.61%)
Brian Rogers 2,750,000 sh (+25%)
Robert Olstein 93,000 sh (+12.05%)
Murray Stahl 7,400 sh (+11.28%)
Chuck Royce 171,100 sh (+9.79%)
Diamond Hill Capital 2,049,646 sh (+4.86%)
Bernard Horn 42,933 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY 2,017,600 sh (-3.74%)
David Dreman 29,218 sh (-28.19%)
Alan Fournier 237,778 sh (-44.14%)
Jeremy Grantham 377,008 sh (-74.28%)
» More
Q1 2014

DGX Guru Trades in Q1 2014

Louis Moore Bacon 7,800 sh (New)
Chris Davis 102,337 sh (New)
Ray Dalio 78,977 sh (New)
Larry Robbins 1,951,300 sh (New)
Manning & Napier Advisors, Inc 191,490 sh (New)
Paul Tudor Jones 406,067 sh (+1421.48%)
Steven Cohen 110,044 sh (+72.77%)
David Dreman 48,748 sh (+66.84%)
Bernard Horn 61,733 sh (+43.79%)
HOTCHKIS & WILEY 2,495,500 sh (+23.69%)
Chuck Royce 188,600 sh (+10.23%)
John Rogers 295,159 sh (+10.11%)
Brian Rogers 3,000,000 sh (+9.09%)
Robert Olstein 100,000 sh (+7.53%)
Murray Stahl 7,850 sh (+6.08%)
Jeff Auxier 80,350 sh (unchged)
Alan Fournier Sold Out
Richard Pzena 972,200 sh (-19.99%)
Joel Greenblatt 76,412 sh (-72.63%)
Jeremy Grantham 91,500 sh (-75.73%)
Diamond Hill Capital 253,642 sh (-87.63%)
» More
Q2 2014

DGX Guru Trades in Q2 2014

Scott Black 220 sh (New)
Chris Davis 4,672,681 sh (+4465.97%)
Louis Moore Bacon 14,460 sh (+85.38%)
John Rogers 352,928 sh (+19.57%)
HOTCHKIS & WILEY 2,523,400 sh (+1.12%)
Manning & Napier Advisors, Inc 193,424 sh (+1.01%)
Bernard Horn 61,733 sh (unchged)
Steven Cohen 155,400 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Larry Robbins Sold Out
Jeremy Grantham Sold Out
Chuck Royce 187,500 sh (-0.58%)
Jeff Auxier 79,000 sh (-1.68%)
Murray Stahl 7,050 sh (-10.19%)
Robert Olstein 82,000 sh (-18%)
David Dreman 35,982 sh (-26.19%)
Diamond Hill Capital 124,800 sh (-50.8%)
Richard Pzena 431,100 sh (-55.66%)
Ray Dalio 13,545 sh (-82.85%)
Joel Greenblatt 4,384 sh (-94.26%)
Paul Tudor Jones 8,400 sh (-97.93%)
» More
Q3 2014

DGX Guru Trades in Q3 2014

Joel Greenblatt 238,057 sh (+5330.13%)
Ray Dalio 15,626 sh (+15.36%)
Chuck Royce 213,000 sh (+13.6%)
Murray Stahl 7,750 sh (+9.93%)
Chris Davis 4,879,416 sh (+4.42%)
Manning & Napier Advisors, Inc 195,674 sh (+1.16%)
Bernard Horn 61,733 sh (unchged)
Robert Olstein 82,000 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Scott Black Sold Out
Louis Moore Bacon Sold Out
Diamond Hill Capital Sold Out
Jeff Auxier 78,950 sh (-0.06%)
Richard Pzena 429,700 sh (-0.32%)
John Rogers 348,910 sh (-1.14%)
David Dreman 33,898 sh (-5.79%)
HOTCHKIS & WILEY 1,593,262 sh (-36.86%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-09-30 Reduce -36.86%0.19%$59.28 - $64.08 $ 64.434%1593262
Joel Greenblatt 2014-09-30 Add 5330.13%0.14%$59.28 - $64.08 $ 64.434%238057
Scott Black 2014-09-30 Sold Out $59.28 - $64.08 $ 64.434%0
Chris Davis 2014-06-30 Add 4465.97%0.8%$55.5 - $61.75 $ 64.4310%4672681
Richard Pzena 2014-06-30 Reduce -55.66%0.18%$55.5 - $61.75 $ 64.4310%431100
Robert Olstein 2014-06-30 Reduce -18%0.14%$55.5 - $61.75 $ 64.4310%82000
David Dreman 2014-06-30 Reduce -26.19%0.06%$55.5 - $61.75 $ 64.4310%35982
Joel Greenblatt 2014-06-30 Reduce -94.26%0.06%$55.5 - $61.75 $ 64.4310%4384
Ray Dalio 2014-06-30 Reduce -82.85%0.03%$55.5 - $61.75 $ 64.4310%13545
Scott Black 2014-06-30 New Buy$55.5 - $61.75 $ 64.4310%220
Joel Greenblatt 2014-03-31 Reduce -72.63%0.26%$50.8 - $57.99 $ 64.4320%76412
HOTCHKIS & WILEY 2014-03-31 Add 23.69%0.1%$50.8 - $57.99 $ 64.4320%2495500
David Dreman 2014-03-31 Add 66.84%0.09%$50.8 - $57.99 $ 64.4320%48748
Ray Dalio 2014-03-31 New Buy0.04%$50.8 - $57.99 $ 64.4320%78977
Chris Davis 2014-03-31 New Buy0.02%$50.8 - $57.99 $ 64.4320%102337
Joel Greenblatt 2013-12-31 Add 533.63%0.3%$52.79 - $63.7 $ 64.438%279188
Richard Pzena 2013-12-31 Add 81.17%0.17%$52.79 - $63.7 $ 64.438%1215050
John Rogers 2013-12-31 Add 447.73%0.15%$52.79 - $63.7 $ 64.438%268053
Brian Rogers 2013-12-31 Add 25%0.11%$52.79 - $63.7 $ 64.438%2750000
David Dreman 2013-12-31 Reduce -28.19%0.06%$52.79 - $63.7 $ 64.438%29218
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Aug 07, 2014

The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Quest Diagnostics - Mar 05, 2014

Medical diagnostic testing provider Quest Diagnostics, Inc. (DGX) underperformed due to weakness in both volumes and pricing.



From Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2013 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

DGX: A Healthy Diagnosis
How much are you paying for the revenue of companies in your portfolio? The less you pay per dollar of revenue, the better. Why? Because revenue translates into earning power, and as we know, when earnings grow, they pull up stock prices. As with almost any asset, buying for less is best if it's an investment of some kind. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Bernard Horn Comments on Quest Diagnostics
The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations. Read more...
Medical Diagnostic Labs Facing Medicare Headwinds
Currently medical diagnostic lab stocks are trading at near historical lows for price-to-sales (P/S). At first sight these companies might look like bargains, but lower p/s ratios might be the new normal for these companies. I have taken a closer look at Lab Corp of America (LH), Quest Diagnostics (DGX), and Bio-Reference Labs (BRLI). Read more...
Diamond Hill Capital Comments on Quest Diagnostics
Medical diagnostic testing provider Quest Diagnostics, Inc. (DGX) underperformed due to weakness in both volumes and pricing. Read more...
Numerous Gurus Hold IDCC, DGX, PTR at 10-Year Low P/B
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, InterDigital Inc. (IDCC), Quest Diagnostics Inc. (DGX) and PetroChina Co. Ltd. (PTR) are held by numerous gurus and are traded at or near their 10-year low. Furthermore, insiders are selling IDCC and DGX. Read more...
DGX, STO, LSE:DOM - Gurus Hold Stocks Traded at 10-Year Low P/B
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, Quest Diagnostics Inc. (DGX), Statoil ASA (STO) and Domino’s Pizza Group PLC (LSE:DOM) are stocks owned by gurus and traded at or near their 10-year historical low P/B ratios. Check out these company updates and trade highlights as of the third quarter of 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.60
DGX's P/E(ttm) is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 18.60 )
DGX' s 10-Year P/E(ttm) Range
Min: 9.14   Max: 31.21
Current: 18.6

9.14
31.21
P/B 2.20
DGX's P/B is ranked higher than
84% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. DGX: 2.20 )
DGX' s 10-Year P/B Range
Min: 1.85   Max: 4.43
Current: 2.2

1.85
4.43
P/S 1.30
DGX's P/S is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. DGX: 1.30 )
DGX' s 10-Year P/S Range
Min: 1.03   Max: 2.21
Current: 1.3

1.03
2.21
PFCF 17.10
DGX's PFCF is ranked higher than
96% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 17.10 )
DGX' s 10-Year PFCF Range
Min: 8.22   Max: 21.58
Current: 17.1

8.22
21.58
EV-to-EBIT 13.09
DGX's EV-to-EBIT is ranked higher than
93% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 13.09 )
DGX' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 14.3
Current: 13.09

7.3
14.3
PEG 2.74
DGX's PEG is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 2.74 )
DGX' s 10-Year PEG Range
Min: 0.51   Max: 4.29
Current: 2.74

0.51
4.29
Shiller P/E 15.70
DGX's Shiller P/E is ranked higher than
100% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 15.70 )
DGX' s 10-Year Shiller P/E Range
Min: 12.76   Max: 47.22
Current: 15.7

12.76
47.22
Current Ratio 1.31
DGX's Current Ratio is ranked higher than
53% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. DGX: 1.31 )
DGX' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.15
Current: 1.31

0.74
2.15
Quick Ratio 1.22
DGX's Quick Ratio is ranked higher than
55% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. DGX: 1.22 )
DGX' s 10-Year Quick Ratio Range
Min: 0.7   Max: 2.03
Current: 1.22

0.7
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
DGX's Dividend Yield is ranked higher than
74% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.27 vs. DGX: 2.00 )
DGX' s 10-Year Dividend Yield Range
Min: 0.35   Max: 2.36
Current: 2

0.35
2.36
Dividend Payout 0.37
DGX's Dividend Payout is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.37 )
DGX' s 10-Year Dividend Payout Range
Min: 0.09   Max: 0.86
Current: 0.37

0.09
0.86
Dividend growth (3y) 55.40
DGX's Dividend growth (3y) is ranked higher than
94% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.10 vs. DGX: 55.40 )
DGX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 55.4
Current: 55.4

0
55.4
Yield on cost (5-Year) 8.48
DGX's Yield on cost (5-Year) is ranked higher than
90% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.52 vs. DGX: 8.48 )
DGX' s 10-Year Yield on cost (5-Year) Range
Min: 1.48   Max: 10.01
Current: 8.48

1.48
10.01
Share Buyback Rate 4.80
DGX's Share Buyback Rate is ranked higher than
97% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.40 vs. DGX: 4.80 )
DGX' s 10-Year Share Buyback Rate Range
Min: 0   Max: -17.7
Current: 4.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
DGX's Price/DCF (Projected) is ranked higher than
99% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.80 )
DGX' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 4.46
Current: 0.8

0.65
4.46
Price/Median PS Value 0.90
DGX's Price/Median PS Value is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. DGX: 0.90 )
DGX' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.61
Current: 0.9

0.23
1.61
Price/Peter Lynch Fair Value 2.80
DGX's Price/Peter Lynch Fair Value is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 2.80 )
DGX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 3.48
Current: 2.8

0.62
3.48
Earnings Yield (Greenblatt) 7.60
DGX's Earnings Yield (Greenblatt) is ranked higher than
93% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. DGX: 7.60 )
DGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7   Max: 13.7
Current: 7.6

7
13.7
Forward Rate of Return (Yacktman) 13.83
DGX's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. DGX: 13.83 )
DGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.9   Max: 34.7
Current: 13.83

11.9
34.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, LIFE, ENZ, IDXX » details
Traded in other countries:QDI.Germany
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the largest medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
DGX: A Healthy Diagnosis Oct 08 2014 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Bernard Horn Comments on Quest Diagnostics Aug 07 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S May 28 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/S May 13 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 05 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S Apr 29 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 28 2014 

More From Other Websites
OPTIMIZERx Corp. to Automate Patient Savings and Improve Medication Adherence for Patients Served by... Nov 17 2014
OPTIMIZERx Corp. to Automate Patient Savings and Improve Medication Adherence for Patients Served by... Nov 17 2014
Quest Diagnostics upgraded by Deutsche Bank Nov 13 2014
QUEST DIAGNOSTICS INC Financials Nov 06 2014
QUEST DIAGNOSTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 05 2014
Quest Diagnostics (DGX): Stock With Unusual Social Activity Nov 05 2014
Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents... Nov 05 2014
Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents... Nov 05 2014
Quest Diagnostics Introduces BRCAvantage Plus™, Providing New Choices in Genetic Breast Cancer... Nov 04 2014
LabCorp Diversifies With $6.1 billion Covance Buyout Nov 03 2014
10-Q for Quest Diagnostics, Inc. Nov 01 2014
QUEST DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report Oct 30 2014
LabCorp Outshines Earnings, Revenues in Q3; Guides Up Oct 28 2014
Quest Diagnostics Beats on Earnings & Revs, Ups View Oct 23 2014
Quest Diagnostics Inc Earnings Call scheduled for 8:30 am ET today Oct 23 2014
[$$] Quest Diagnostics Sees Revenue Increase Oct 23 2014
Quest Diagnostics beats Street 3Q forecasts Oct 23 2014
Quest Diagnostics beats Street 3Q forecasts Oct 23 2014
Q3 2014 Quest Diagnostics Inc Earnings Release - Before Market Open Oct 23 2014
QUEST DIAGNOSTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK